Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.
about
The lipid phosphatase activity of PTEN is critical for its tumor supressor functionSTEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumorsInteraction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinaseEvidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTENX-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalizationPTEN inhibits BMI1 function independently of its phosphatase activityPTEN function: how normal cells control it and tumour cells lose itGenes other than BRCA1 and BRCA2 involved in breast cancer susceptibilityDeletion, mutation, and loss of expression of KLF6 in human prostate cancerPten dose dictates cancer progression in the prostateAdvances in genetics: widening our understanding of prostate cancerIncorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerThe androgen receptor and stem cell pathways in prostate and bladder cancers (review)Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.Therapeutic targeting of cancers with loss of PTEN function.FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancerMechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cellsMale breast cancer in Cowden syndrome patients with germline PTEN mutationsLoss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cellsModulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screeningCombined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in ChordomaShank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cellsAdenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway.MYC oncogenes and human neoplastic disease.Endogenous antibodies for tumor detectionSGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.PTEN gene and integrin signaling in cancer.Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons.PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumor suppressor lipid phosphatase.Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.
P2860
Q22007981-B6091C86-0680-41FA-8D84-A026DFFC698DQ22010908-88B89269-0E6A-4E51-A5AF-31DB6C5F440EQ22253438-36441491-87D2-4508-ADD7-0B3E3C46F2EFQ22253866-D0347817-EBEC-4DFD-870C-713D0E1CBAF0Q22254699-860A5A62-491B-4ED1-99E2-AE98EEBF07BFQ24292919-FE4B8287-C5C8-4030-8516-4C962C53DAFEQ24314543-D6B81DAE-4A57-44B4-A85C-A322F61E908CQ24315949-CE029D23-5164-4ED4-996A-E827146731EAQ24528114-C8F5FB1F-EAEE-48E6-8EB4-00B0A0507615Q24679438-3594C9D2-DDBD-4869-88CD-8CAF82F49B31Q24684163-E1B8B001-E05C-46EB-A7D0-9BEB8F221700Q24791909-80847BF2-16B3-4F26-B17E-B90CF0E08DE9Q26740628-8C213881-9093-4395-901A-0D51A9EF9567Q26752510-7D2D9438-84AB-45E6-8689-220DFBD6F24DQ26773634-CF6780C9-08D7-4024-B8B3-2F194894E0DEQ26853232-924E3816-C322-4C74-BBEB-6ABA444D4907Q27824772-CCDA48DA-8ADE-498B-AD38-EF57176050CAQ27851411-DB7A20E3-DCB5-4A7D-853B-9EEF3832A1B7Q27852764-3D520084-0F12-48F5-BB44-7B8BCC0E0C2EQ28204251-D4EDFB50-9C35-4757-87A7-56449874B115Q28236579-CB666EB4-3062-4CB3-BA51-122D088881B0Q28359884-0A39D610-5207-4FF9-83E8-D53A44D1EA51Q28388722-545A0BA8-3203-4158-B3DC-174DBDC017B0Q28482249-2BE6FA62-ACBF-41D1-A17C-91C560B684D5Q30278895-0BC14EDE-4159-47E9-AC7E-272CA44037C5Q30494717-112C2923-087F-4CEB-8686-0D13B4714A1FQ30654792-100DBEAC-A49A-458D-82C3-36E56FCE4031Q33385228-D1F16B37-5AE4-4B53-929C-91E13F5F6A1BQ33389796-A716A5C7-AC80-4E8E-A871-43C0DC63399BQ33599964-B602071D-BE70-42F6-A555-08AE2F768DD5Q33667340-9C9A8D5C-9C0D-4DEF-890F-4682C745F8C0Q33687275-9C450776-2D6D-42F5-9794-C198B122C7D6Q33701389-A446A075-110B-4FF4-9439-07F5DB85A25BQ33723651-94A2BE1C-FA80-4938-98A4-3BD835264537Q33765703-79F85195-1EBC-4063-BB76-F061E199C3F4Q33774967-28A3EE57-3ACD-46D7-8080-90AEF1879219Q33869038-64C8B9EA-F997-48CF-A5E6-2FCAA8C65040Q33895062-E4DDC40C-46A9-4989-9C7F-76526A77AB8CQ33940647-9AC183D6-7D71-473D-A281-8ACDA68A538CQ33942901-FE066F0C-FD73-4F4C-848D-41DA914A517A
P2860
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Inactivation of the tumor supp ...... er through loss of expression.
@ast
Inactivation of the tumor supp ...... er through loss of expression.
@en
type
label
Inactivation of the tumor supp ...... er through loss of expression.
@ast
Inactivation of the tumor supp ...... er through loss of expression.
@en
prefLabel
Inactivation of the tumor supp ...... er through loss of expression.
@ast
Inactivation of the tumor supp ...... er through loss of expression.
@en
P2093
P2860
P356
P1476
Inactivation of the tumor supp ...... er through loss of expression.
@en
P2093
C L Sawyers
R E Reiter
R L Vessella
W B Isaacs
P2860
P304
P356
10.1073/PNAS.95.9.5246
P407
P577
1998-04-01T00:00:00Z